Bipartisan group of lawmakers opposes Biden’s plan to use ‘march-in’ to lower drug prices

A group of 28 sen­a­tors and mem­bers of Con­gress, in­clud­ing nine De­moc­rats, sent a let­ter to Pres­i­dent Joe Biden on Wednes­day de­cry­ing his ad­min­is­tra­tion’s re­cent pro­pos­al to ex­er­cise its so-called march-in rights when drug prices rise too high.

Biden’s plan, un­veiled in De­cem­ber in guid­ance from the Na­tion­al In­sti­tute of Stan­dards and Tech­nol­o­gy, would al­low the gov­ern­ment to con­sid­er the price of a drug when de­cid­ing whether to take over patents on in­ven­tions de­vel­oped with the help of fed­er­al­ly-fund­ed re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.